FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2462261615> ?p ?o ?g. }

• W2462261615 endingPage "333" @default.
• W2462261615 startingPage "333" @default.
• W2462261615 abstract "Edaravone, a synthetic-free radical scavenger, has been reported to reduce ischemia-reperfusion-induced renal injury by improving tubular cell function, and lowering serum creatinine and renal vascular resistance. The present study investigated the effect of edaravone in diabetes mellitus-induced nephropathy in rats. A single administration of streptozotocin (STZ, 55 mg/kg, i.p.) was employed to induce diabetes mellitus in rats. The STZ-administered diabetic rats were allowed for 10 weeks to develop nephropathy. Mean body weight, lipid alteration, renal functional and histopathology were analysed. Diabetic rats developed nephropathy as evidenced by a significant increase in serum creatinine and urea, and marked renal histopathological abnormalities like glomerulosclerosis and tubular cell degeneration. The kidney weight to body weight ratio was increased. Moreover, diabetic rats showed lipid alteration as evidenced by a signifi cant increase in serum triglycerides and decrease in serum high-density lipoproteins. Edaravone (10 mg/kg, i.p., last 4-weeks) treatment markedly prevented the development of nephropathy in diabetic rats by reducing serum creatinine and urea and preventing renal structural abnormalities. In addition, its treatment, without significantly altering the elevated glucose level in diabetic rats, prevented diabetes mellitus-induced lipid alteration by reducing serum triglycerides and increasing serum high-density lipoproteins. Interestingly, the renoprotective effect of edaravone was comparable to that of lisinopril (5 mg/kg, p.o, 4 weeks, standard drug). Edaravone prevented renal structural and functional abnormalities and lipid alteration associated with experimental diabetes mellitus. Edaravone has a potential to prevent nephropathy without showing an anti-diabetic action, implicating its direct renoprotection in diabetic rats." @default.
• W2462261615 created "2016-07-22" @default.
• W2462261615 creator A5012455750 @default.
• W2462261615 creator A5014620561 @default.
• W2462261615 creator A5020875687 @default.
• W2462261615 creator A5028357007 @default.
• W2462261615 creator A5033920623 @default.
• W2462261615 creator A5065897870 @default.
• W2462261615 creator A5066808564 @default.
• W2462261615 creator A5069686944 @default.
• W2462261615 creator A5070083734 @default.
• W2462261615 creator A5083798764 @default.
• W2462261615 creator A5085387912 @default.
• W2462261615 creator A5089697600 @default.
• W2462261615 date "2016-01-01" @default.
• W2462261615 modified "2023-10-01" @default.
• W2462261615 title "Effect of edaravone in diabetes mellitus-induced nephropathy in rats" @default.
• W2462261615 cites W1975298621 @default.
• W2462261615 cites W1987181917 @default.
• W2462261615 cites W1994791100 @default.
• W2462261615 cites W2007108839 @default.
• W2462261615 cites W2011212393 @default.
• W2462261615 cites W2015546180 @default.
• W2462261615 cites W2023130651 @default.
• W2462261615 cites W2030384420 @default.
• W2462261615 cites W2035142450 @default.
• W2462261615 cites W2043070915 @default.
• W2462261615 cites W2054978262 @default.
• W2462261615 cites W2061172276 @default.
• W2462261615 cites W2072903689 @default.
• W2462261615 cites W2075960777 @default.
• W2462261615 cites W2084026571 @default.
• W2462261615 cites W2087475545 @default.
• W2462261615 cites W2091712060 @default.
• W2462261615 cites W2097084078 @default.
• W2462261615 cites W2108250096 @default.
• W2462261615 cites W2120293565 @default.
• W2462261615 cites W2124946547 @default.
• W2462261615 cites W2127464066 @default.
• W2462261615 cites W2142564261 @default.
• W2462261615 cites W2149433215 @default.
• W2462261615 cites W2208212778 @default.
• W2462261615 cites W2441153570 @default.
• W2462261615 doi "https://doi.org/10.4196/kjpp.2016.20.4.333" @default.
• W2462261615 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4930901" @default.
• W2462261615 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27382349" @default.
• W2462261615 hasPublicationYear "2016" @default.
• W2462261615 type Work @default.
• W2462261615 sameAs 2462261615 @default.
• W2462261615 citedByCount "5" @default.
• W2462261615 countsByYear W24622616152017 @default.
• W2462261615 countsByYear W24622616152019 @default.
• W2462261615 countsByYear W24622616152020 @default.
• W2462261615 countsByYear W24622616152022 @default.
• W2462261615 countsByYear W24622616152023 @default.
• W2462261615 crossrefType "journal-article" @default.
• W2462261615 hasAuthorship W2462261615A5012455750 @default.
• W2462261615 hasAuthorship W2462261615A5014620561 @default.
• W2462261615 hasAuthorship W2462261615A5020875687 @default.
• W2462261615 hasAuthorship W2462261615A5028357007 @default.
• W2462261615 hasAuthorship W2462261615A5033920623 @default.
• W2462261615 hasAuthorship W2462261615A5065897870 @default.
• W2462261615 hasAuthorship W2462261615A5066808564 @default.
• W2462261615 hasAuthorship W2462261615A5069686944 @default.
• W2462261615 hasAuthorship W2462261615A5070083734 @default.
• W2462261615 hasAuthorship W2462261615A5083798764 @default.
• W2462261615 hasAuthorship W2462261615A5085387912 @default.
• W2462261615 hasAuthorship W2462261615A5089697600 @default.
• W2462261615 hasBestOaLocation W24622616151 @default.
• W2462261615 hasConcept C126322002 @default.
• W2462261615 hasConcept C134018914 @default.
• W2462261615 hasConcept C159641895 @default.
• W2462261615 hasConcept C2777390665 @default.
• W2462261615 hasConcept C2778176769 @default.
• W2462261615 hasConcept C2779280383 @default.
• W2462261615 hasConcept C2779554857 @default.
• W2462261615 hasConcept C2779561371 @default.
• W2462261615 hasConcept C2779922275 @default.
• W2462261615 hasConcept C2780091579 @default.
• W2462261615 hasConcept C2780306776 @default.
• W2462261615 hasConcept C2781184683 @default.
• W2462261615 hasConcept C555293320 @default.
• W2462261615 hasConcept C71924100 @default.
• W2462261615 hasConceptScore W2462261615C126322002 @default.
• W2462261615 hasConceptScore W2462261615C134018914 @default.
• W2462261615 hasConceptScore W2462261615C159641895 @default.
• W2462261615 hasConceptScore W2462261615C2777390665 @default.
• W2462261615 hasConceptScore W2462261615C2778176769 @default.
• W2462261615 hasConceptScore W2462261615C2779280383 @default.
• W2462261615 hasConceptScore W2462261615C2779554857 @default.
• W2462261615 hasConceptScore W2462261615C2779561371 @default.
• W2462261615 hasConceptScore W2462261615C2779922275 @default.
• W2462261615 hasConceptScore W2462261615C2780091579 @default.
• W2462261615 hasConceptScore W2462261615C2780306776 @default.
• W2462261615 hasConceptScore W2462261615C2781184683 @default.
• W2462261615 hasConceptScore W2462261615C555293320 @default.
• W2462261615 hasConceptScore W2462261615C71924100 @default.
• W2462261615 hasIssue "4" @default.

• next